Literature DB >> 10688610

Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.

F Rakhshan1, T A Day, R D Blakely, E L Barker.   

Abstract

Anandamide (N-arachidonylethanolamide) is an endogenous cannabinoid that mimics the pharmacologic effects of Delta(9)-tetrahydrocannabinol, the major bioactive substance in marijuana. Anandamide appears to be synthesized, released, and inactivated by mechanisms similar to those for other neurotransmitters. Of interest to the present studies are reports that anandamide undergoes carrier-mediated uptake into neuronal or glial cells after release, followed by rapid intracellular degradation by the intracellular fatty acid amidohydrolase. In addition to effects in the brain, anandamide has multiple effects in the periphery, particularly on cells of the immune system that express both a peripheral cannabinoid receptor and amidohydrolase enzyme. We have performed a detailed characterization of anandamide uptake in the cognate mast cell line RBL-2H3 to test the hypothesis that the uptake system in peripheral cells is also carrier-mediated and functionally similar to that observed in the central nervous system. RBL-2H3 cells exhibited robust, saturable transport of [(3)H]anandamide that was both time- and temperature-sensitive. This transport activity was not dependent on extracellular ion gradients for uptake and was inhibited selectively by other fatty acid-derived molecules, anandamide congeners, and the psychoactive cannabinoids such as Delta(9)-tetrahydrocannabinol. We conclude that anandamide transport in the RBL-2H3 cells is carrier-mediated, and uptake in peripheral cells is functionally and pharmacologically identical with that observed in neurons and astrocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688610

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

1.  Pitfalls and solutions in assaying anandamide transport in cells.

Authors:  Sergio Oddi; Filomena Fezza; Giuseppina Catanzaro; Chiara De Simone; Mariangela Pucci; Daniele Piomelli; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Lipid Res       Date:  2010-05-06       Impact factor: 5.922

2.  Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells.

Authors:  Mireille Alhouayek; Linda Rankin; Sandra Gouveia-Figueira; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2018-02-05       Impact factor: 8.739

3.  Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.

Authors:  L Thors; J Eriksson; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

Review 4.  Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide.

Authors:  Matthew J McFarland; Ekaterina A Terebova; Eric L Barker
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

5.  Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.

Authors:  Sandra Holt; Christopher J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

Review 6.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

7.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 8.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.